Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ACRV 
Acrivon Therapeutics, Inc. Common Stock (ACRV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/03/2025: ACRV (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $11.17
1 Year Target Price $11.17
| 4 | Strong Buy |
| 4 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -28.98% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 69.42M USD | Price to earnings Ratio - | 1Y Target Price 11.17 |
Price to earnings Ratio - | 1Y Target Price 11.17 | ||
Volume (30-day avg) 9 | Beta 1.84 | 52 Weeks Range 1.05 - 8.00 | Updated Date 12/3/2025 |
52 Weeks Range 1.05 - 8.00 | Updated Date 12/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.93 |
Earnings Date
Report Date 2025-11-06 | When - | Estimate -1.16 | Actual -0.47 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -30.89% | Return on Equity (TTM) -50.23% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -51794903 | Price to Sales(TTM) - |
Enterprise Value -51794903 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.43 | Shares Outstanding 31555126 | Shares Floating 16857064 |
Shares Outstanding 31555126 | Shares Floating 16857064 | ||
Percent Insiders 20.57 | Percent Institutions 56.58 |
Upturn AI SWOT
Acrivon Therapeutics, Inc. Common Stock
Company Overview
History and Background
Acrivon Therapeutics, Inc. is a biopharmaceutical company focused on developing precision medicines for cancer. Founded in 2009 by Peter Blume-Jensen and based in Watertown, MA, it leverages its Acrivon Predictive Precision medicine (APM) platform to identify patients most likely to benefit from its therapies. Went public in January 2024.
Core Business Areas
- Precision Oncology: Develops and commercializes predictive precision medicine (PPM) oncology therapies, utilizing its proprietary APM platform.
- Drug Development: Discovers and develops new cancer treatments through targeted therapies based on patient-specific responses.
- Biomarker Discovery: Focuses on identifying and validating biomarkers to predict treatment response in cancer patients.
Leadership and Structure
Peter Blume-Jensen, MD, PhD is the President and CEO. The company has a board of directors and several departments including research & development, clinical development, and business operations.
Top Products and Market Share
Key Offerings
- ACR-368: A selective inhibitor of CHK1 and CHK2 kinases in Phase 2 clinical trials for cancers. Market share data is not yet available as the product is not yet approved. Competitors include companies developing CHK1/2 inhibitors such as Artios Pharma and Repare Therapeutics.
- APM Platform: Acrivon Predictive Precision medicine (APM) platform used for patient selection in clinical trials. Not directly revenue generating but critical for the company's strategy. Competitors developing similar companion diagnostics and personalized medicine strategies include Foundation Medicine and Guardant Health.
Market Dynamics
Industry Overview
The oncology market is experiencing rapid growth, driven by advancements in personalized medicine and targeted therapies. There is increasing demand for predictive biomarkers to improve treatment outcomes.
Positioning
Acrivon is positioned as a leader in predictive precision medicine in oncology, differentiating itself through its APM platform, which helps improve clinical trial outcomes.
Total Addressable Market (TAM)
The global oncology market is estimated to reach over $500 billion by 2030. Acrivon is positioned to capture a portion of this market through its targeted therapies and predictive capabilities, with a focus on identifying and treating patients most likely to respond to their drugs.
Upturn SWOT Analysis
Strengths
- Proprietary APM platform
- Focus on personalized medicine
- Experienced leadership team
- Strong intellectual property portfolio
Weaknesses
- Limited number of products in the pipeline
- Reliance on clinical trial success
- High R&D costs
- Early stage commercialization
Opportunities
- Expansion of APM platform to other cancers
- Partnerships with pharmaceutical companies
- Potential for breakthrough therapies
- Increasing demand for personalized medicine
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- ARRY
- FMI
- Guardant Health (GH)
Competitive Landscape
Acrivon's APM platform differentiates it, but success depends on demonstrating its value in clinical trials and commercialization. Large pharmaceutical companies also compete in the broader oncology market.
Growth Trajectory and Initiatives
Historical Growth: Limited historical data available as a newly public company.
Future Projections: Growth projections are based on successful clinical trial outcomes and regulatory approvals. Analyst estimates will vary. Refer to analyst reports for specific revenue and earnings forecasts.
Recent Initiatives: Recent initiatives focus on advancing ACR-368 through clinical trials and expanding the applications of the APM platform.
Summary
Acrivon Therapeutics is a newly public biopharmaceutical company focusing on precision oncology and leveraging its APM platform to personalize cancer treatment. The company shows promise through its technology and strategic approach, but faces challenges typical of early-stage biotech firms, including clinical trial risks and high R&D expenses. Acrivon needs to successfully advance its lead compound, ACR-368, and validate the APM platform's clinical utility to secure its position in the market. Investors should watch for clinical trial results, partnerships, and progress in expanding the APM platform.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Acrivon Therapeutics, Inc. SEC filings
- Company website
- Press releases
- Analyst reports (where available)
- Market research reports on the oncology market
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share and competitive data are estimates and may vary based on source and methodology. Forward-looking statements are subject to risks and uncertainties.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Acrivon Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters Watertown, MA, United States | ||
IPO Launch date 2022-11-15 | Co-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer Dr. Peter Blume-Jensen M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 75 | Website https://acrivon.com |
Full time employees 75 | Website https://acrivon.com | ||
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.